Glimepirida Stada (Glimepiride)

Glimepirida Stada is indicated for the oral treatment of type 2 diabetes mellitus in adults when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

• As monotherapy in patients newly diagnosed with type 2 diabetes who do not achieve target glucose levels with lifestyle measures alone.
• As add‑on therapy to metformin or other oral antidiabetic agents when additional glucose lowering is required.
• In combination with basal insulin for patients who need further reduction in HbA1c.
• For patients with stable renal function who can tolerate sulfonylureas.

The safety profile of Glimepirida Stada includes both frequently observed and less common adverse reactions.

Common

• Mild hypoglycemia manifested by shakiness, sweating, or hunger, usually occurring if a dose is taken without adequate food.
• Nausea, occasional vomiting, or general abdominal discomfort.
• Headache of mild to moderate intensity.
• Dizziness or a sensation of light‑headedness, particularly after standing quickly.

Serious

• Severe hypoglycemia that may cause confusion, loss of consciousness, or seizures and requires immediate medical attention.
• Allergic reactions including skin rash, pruritus, urticaria, or angio‑edema that may affect breathing.
• Hematologic changes such as leukopenia, neutropenia, or thrombocytopenia reported in rare cases.

Before prescribing Glimepirida Stada, clinicians should evaluate several patient‑specific factors to minimize risk.

• Assess renal and hepatic function; dose adjustment may be needed in impairment.
• Review history of cardiovascular disease, as sulfonylureas can affect cardiac ischemic preconditioning.
• Verify that the patient is not pregnant or breastfeeding; safety data are limited.
• Caution in elderly patients due to increased susceptibility to hypoglycemia.
• Avoid use in patients with known hypersensitivity to glimepiride or other sulfonylureas.
• Monitor for signs of hypoglycemia when initiating therapy or changing dose.

Glimepirida Stada can interact with other medicines, affecting blood glucose levels or increasing the risk of adverse events.

Avoid

• Concomitant use with other sulfonylureas or insulin that may cause additive hypoglycemia.
• Strong CYP2C9 inhibitors such as fluconazole or amiodarone, which can raise glimepiride concentrations.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, which can reduce glucose tolerance and require closer monitoring.
• Antifungal agents like itraconazole or certain macrolide antibiotics that moderately inhibit CYP2C9.
• Warfarin, as glimepiride may alter INR and require more frequent coagulation monitoring.